Table of Content

1 Report Overview
1.1 Granulomatosis with Polyangiitis Drug Definition
1.2 Market by Type
1.2.1 Global Granulomatosis with Polyangiitis Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Benralizumab
1.2.3 Avacopan
1.2.4 Rituximab Biosimilar
1.2.5 Others
1.3 Market Segment by Application
1.3.1 Global Granulomatosis with Polyangiitis Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Granulomatosis with Polyangiitis Drug Sales
2.1 Global Granulomatosis with Polyangiitis Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Granulomatosis with Polyangiitis Drug Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Granulomatosis with Polyangiitis Drug Revenue by Region
2.3.1 Global Granulomatosis with Polyangiitis Drug Revenue by Region (2018-2024)
2.3.2 Global Granulomatosis with Polyangiitis Drug Revenue by Region (2024-2034)
2.4 Global Granulomatosis with Polyangiitis Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Granulomatosis with Polyangiitis Drug Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Granulomatosis with Polyangiitis Drug Sales Quantity by Region
2.6.1 Global Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2018-2024)
2.6.2 Global Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Granulomatosis with Polyangiitis Drug Sales Quantity by Manufacturers
3.1.1 Global Granulomatosis with Polyangiitis Drug Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Granulomatosis with Polyangiitis Drug Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Granulomatosis with Polyangiitis Drug Sales in 2022
3.2 Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturers
3.2.1 Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global Granulomatosis with Polyangiitis Drug Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Granulomatosis with Polyangiitis Drug Revenue in 2022
3.3 Global Granulomatosis with Polyangiitis Drug Sales Price by Manufacturers
3.4 Global Key Players of Granulomatosis with Polyangiitis Drug, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Granulomatosis with Polyangiitis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Granulomatosis with Polyangiitis Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Granulomatosis with Polyangiitis Drug, Product Offered and Application
3.8 Global Key Manufacturers of Granulomatosis with Polyangiitis Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Granulomatosis with Polyangiitis Drug Sales Quantity by Type
4.1.1 Global Granulomatosis with Polyangiitis Drug Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Granulomatosis with Polyangiitis Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Granulomatosis with Polyangiitis Drug Revenue by Type
4.2.1 Global Granulomatosis with Polyangiitis Drug Historical Revenue by Type (2018-2024)
4.2.2 Global Granulomatosis with Polyangiitis Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2018-2034)
4.3 Global Granulomatosis with Polyangiitis Drug Price by Type
4.3.1 Global Granulomatosis with Polyangiitis Drug Price by Type (2018-2024)
4.3.2 Global Granulomatosis with Polyangiitis Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Granulomatosis with Polyangiitis Drug Sales Quantity by Application
5.1.1 Global Granulomatosis with Polyangiitis Drug Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Granulomatosis with Polyangiitis Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Granulomatosis with Polyangiitis Drug Revenue by Application
5.2.1 Global Granulomatosis with Polyangiitis Drug Historical Revenue by Application (2018-2024)
5.2.2 Global Granulomatosis with Polyangiitis Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2018-2034)
5.3 Global Granulomatosis with Polyangiitis Drug Price by Application
5.3.1 Global Granulomatosis with Polyangiitis Drug Price by Application (2018-2024)
5.3.2 Global Granulomatosis with Polyangiitis Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Granulomatosis with Polyangiitis Drug Sales by Company
6.1.1 North America Granulomatosis with Polyangiitis Drug Revenue by Company (2018-2024)
6.1.2 North America Granulomatosis with Polyangiitis Drug Sales Quantity by Company (2018-2024)
6.2 North America Granulomatosis with Polyangiitis Drug Market Size by Type
6.2.1 North America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Granulomatosis with Polyangiitis Drug Revenue by Type (2018-2034)
6.3 North America Granulomatosis with Polyangiitis Drug Market Size by Application
6.3.1 North America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Granulomatosis with Polyangiitis Drug Revenue by Application (2018-2034)
6.4 North America Granulomatosis with Polyangiitis Drug Market Size by Country
6.4.1 North America Granulomatosis with Polyangiitis Drug Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Granulomatosis with Polyangiitis Drug Revenue by Country (2018-2034)
6.4.3 North America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Granulomatosis with Polyangiitis Drug Sales by Company
7.1.1 Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Company (2018-2024)
7.1.2 Europe Granulomatosis with Polyangiitis Drug Revenue by Company (2018-2024)
7.2 Europe Granulomatosis with Polyangiitis Drug Market Size by Type
7.2.1 Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Granulomatosis with Polyangiitis Drug Revenue by Type (2018-2034)
7.3 Europe Granulomatosis with Polyangiitis Drug Market Size by Application
7.3.1 Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Granulomatosis with Polyangiitis Drug Revenue by Application (2018-2034)
7.4 Europe Granulomatosis with Polyangiitis Drug Market Size by Country
7.4.1 Europe Granulomatosis with Polyangiitis Drug Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2018-2034)
7.4.3 Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Granulomatosis with Polyangiitis Drug Sales by Company
8.1.1 China Granulomatosis with Polyangiitis Drug Sales Quantity by Company (2018-2024)
8.1.2 China Granulomatosis with Polyangiitis Drug Revenue by Company (2018-2024)
8.2 China Granulomatosis with Polyangiitis Drug Market Size by Type
8.2.1 China Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2018-2034)
8.2.2 China Granulomatosis with Polyangiitis Drug Revenue by Type (2018-2034)
8.3 China Granulomatosis with Polyangiitis Drug Market Size by Application
8.3.1 China Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2018-2034)
8.3.2 China Granulomatosis with Polyangiitis Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Granulomatosis with Polyangiitis Drug Sales by Company
9.1.1 APAC Granulomatosis with Polyangiitis Drug Sales Quantity by Company (2018-2024)
9.1.2 APAC Granulomatosis with Polyangiitis Drug Revenue by Company (2018-2024)
9.2 APAC Granulomatosis with Polyangiitis Drug Market Size by Type
9.2.1 APAC Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Granulomatosis with Polyangiitis Drug Revenue by Type (2018-2034)
9.3 APAC Granulomatosis with Polyangiitis Drug Market Size by Application
9.3.1 APAC Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Granulomatosis with Polyangiitis Drug Revenue by Application (2018-2034)
9.4 APAC Granulomatosis with Polyangiitis Drug Market Size by Region
9.4.1 APAC Granulomatosis with Polyangiitis Drug Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Granulomatosis with Polyangiitis Drug Revenue by Region (2018-2034)
9.4.3 APAC Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Bionovis SA
11.1.1 Bionovis SA Company Information
11.1.2 Bionovis SA Overview
11.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Bionovis SA Granulomatosis with Polyangiitis Drug Products and Services
11.1.5 Bionovis SA Granulomatosis with Polyangiitis Drug SWOT Analysis
11.1.6 Bionovis SA Recent Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Information
11.2.2 Bristol-Myers Squibb Company Overview
11.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Products and Services
11.2.5 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug SWOT Analysis
11.2.6 Bristol-Myers Squibb Company Recent Developments
11.3 ChemoCentryx Inc
11.3.1 ChemoCentryx Inc Company Information
11.3.2 ChemoCentryx Inc Overview
11.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Products and Services
11.3.5 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug SWOT Analysis
11.3.6 ChemoCentryx Inc Recent Developments
11.4 Coherus BioSciences Inc
11.4.1 Coherus BioSciences Inc Company Information
11.4.2 Coherus BioSciences Inc Overview
11.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Products and Services
11.4.5 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug SWOT Analysis
11.4.6 Coherus BioSciences Inc Recent Developments
11.5 Genor BioPharma Co Ltd
11.5.1 Genor BioPharma Co Ltd Company Information
11.5.2 Genor BioPharma Co Ltd Overview
11.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Products and Services
11.5.5 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug SWOT Analysis
11.5.6 Genor BioPharma Co Ltd Recent Developments
11.6 GlaxoSmithKline Plc
11.6.1 GlaxoSmithKline Plc Company Information
11.6.2 GlaxoSmithKline Plc Overview
11.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Products and Services
11.6.5 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug SWOT Analysis
11.6.6 GlaxoSmithKline Plc Recent Developments
11.7 Iltoo Pharma
11.7.1 Iltoo Pharma Company Information
11.7.2 Iltoo Pharma Overview
11.7.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Iltoo Pharma Granulomatosis with Polyangiitis Drug Products and Services
11.7.5 Iltoo Pharma Granulomatosis with Polyangiitis Drug SWOT Analysis
11.7.6 Iltoo Pharma Recent Developments
11.8 Panacea Biotec Ltd
11.8.1 Panacea Biotec Ltd Company Information
11.8.2 Panacea Biotec Ltd Overview
11.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Products and Services
11.8.5 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug SWOT Analysis
11.8.6 Panacea Biotec Ltd Recent Developments
11.9 Sandoz International GmbH
11.9.1 Sandoz International GmbH Company Information
11.9.2 Sandoz International GmbH Overview
11.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Products and Services
11.9.5 Sandoz International GmbH Granulomatosis with Polyangiitis Drug SWOT Analysis
11.9.6 Sandoz International GmbH Recent Developments
11.10 The International Biotechnology Center (IBC) Generium
11.10.1 The International Biotechnology Center (IBC) Generium Company Information
11.10.2 The International Biotechnology Center (IBC) Generium Overview
11.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Products and Services
11.10.5 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug SWOT Analysis
11.10.6 The International Biotechnology Center (IBC) Generium Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Granulomatosis with Polyangiitis Drug Value Chain Analysis
12.2 Granulomatosis with Polyangiitis Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Granulomatosis with Polyangiitis Drug Production Mode & Process
12.4 Granulomatosis with Polyangiitis Drug Sales and Marketing
12.4.1 Granulomatosis with Polyangiitis Drug Sales Channels
12.4.2 Granulomatosis with Polyangiitis Drug Distributors
12.5 Granulomatosis with Polyangiitis Drug Customers
13 Market Dynamics
13.1 Granulomatosis with Polyangiitis Drug Industry Trends
13.2 Granulomatosis with Polyangiitis Drug Market Drivers
13.3 Granulomatosis with Polyangiitis Drug Market Challenges
13.4 Granulomatosis with Polyangiitis Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Benralizumab
Table 3. Major Manufacturers of Avacopan
Table 4. Major Manufacturers of Rituximab Biosimilar
Table 5. Major Manufacturers of Others
Table 6. Global Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Granulomatosis with Polyangiitis Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Granulomatosis with Polyangiitis Drug Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2018-2024)
Table 10. Global Granulomatosis with Polyangiitis Drug Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2024-2034)
Table 12. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Pcs)
Table 13. Global Granulomatosis with Polyangiitis Drug Sales by Region (2018-2024) & (K Pcs)
Table 14. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2018-2024)
Table 15. Global Granulomatosis with Polyangiitis Drug Sales by Region (2024-2034) & (K Pcs)
Table 16. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2024-2034)
Table 17. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Manufacturers (2018-2024) & (K Pcs)
Table 18. Global Granulomatosis with Polyangiitis Drug Sales Quantity Share by Manufacturers (2018-2024)
Table 19. Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Granulomatosis with Polyangiitis Drug Revenue Share by Manufacturers (2018-2024)
Table 21. Global Granulomatosis with Polyangiitis Drug Price by Manufacturers 2018-2024 (USD/Pcs)
Table 22. Global Key Players of Granulomatosis with Polyangiitis Drug, Industry Ranking, 2021 VS 2022
Table 23. Global Granulomatosis with Polyangiitis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Granulomatosis with Polyangiitis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Granulomatosis with Polyangiitis Drug as of 2022)
Table 25. Global Key Manufacturers of Granulomatosis with Polyangiitis Drug, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Granulomatosis with Polyangiitis Drug, Product Offered and Application
Table 27. Global Key Manufacturers of Granulomatosis with Polyangiitis Drug, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 30. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 31. Global Granulomatosis with Polyangiitis Drug Sales Quantity Share by Type (2018-2024)
Table 32. Global Granulomatosis with Polyangiitis Drug Sales Quantity Share by Type (2024-2034)
Table 33. Global Granulomatosis with Polyangiitis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Granulomatosis with Polyangiitis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Granulomatosis with Polyangiitis Drug Revenue Share by Type (2018-2024)
Table 36. Global Granulomatosis with Polyangiitis Drug Revenue Share by Type (2024-2034)
Table 37. Granulomatosis with Polyangiitis Drug Price by Type (2018-2024) & (USD/Pcs)
Table 38. Global Granulomatosis with Polyangiitis Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 39. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 40. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 41. Global Granulomatosis with Polyangiitis Drug Sales Quantity Share by Application (2018-2024)
Table 42. Global Granulomatosis with Polyangiitis Drug Sales Quantity Share by Application (2024-2034)
Table 43. Global Granulomatosis with Polyangiitis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Granulomatosis with Polyangiitis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Granulomatosis with Polyangiitis Drug Revenue Share by Application (2018-2024)
Table 46. Global Granulomatosis with Polyangiitis Drug Revenue Share by Application (2024-2034)
Table 47. Granulomatosis with Polyangiitis Drug Price by Application (2018-2024) & (USD/Pcs)
Table 48. Global Granulomatosis with Polyangiitis Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 49. North America Granulomatosis with Polyangiitis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 50. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 51. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 52. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 53. North America Granulomatosis with Polyangiitis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 54. North America Granulomatosis with Polyangiitis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 55. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 56. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 57. North America Granulomatosis with Polyangiitis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 58. North America Granulomatosis with Polyangiitis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 59. North America Granulomatosis with Polyangiitis Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 60. North America Granulomatosis with Polyangiitis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 61. North America Granulomatosis with Polyangiitis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 62. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2018-2024) & (K Pcs)
Table 63. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 64. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 65. Europe Granulomatosis with Polyangiitis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 66. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 67. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 68. Europe Granulomatosis with Polyangiitis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 69. Europe Granulomatosis with Polyangiitis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 70. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 71. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 72. Europe Granulomatosis with Polyangiitis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 73. Europe Granulomatosis with Polyangiitis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 74. Europe Granulomatosis with Polyangiitis Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 75. Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 76. Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 77. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2018-2024) & (K Pcs)
Table 78. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 79. China Granulomatosis with Polyangiitis Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 80. China Granulomatosis with Polyangiitis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 81. China Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 82. China Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 83. China Granulomatosis with Polyangiitis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 84. China Granulomatosis with Polyangiitis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 85. China Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 86. China Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 87. China Granulomatosis with Polyangiitis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 88. China Granulomatosis with Polyangiitis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 89. APAC Granulomatosis with Polyangiitis Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 90. APAC Granulomatosis with Polyangiitis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 91. APAC Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 92. APAC Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 93. APAC Granulomatosis with Polyangiitis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 94. APAC Granulomatosis with Polyangiitis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 95. APAC Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 96. APAC Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 97. APAC Granulomatosis with Polyangiitis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 98. APAC Granulomatosis with Polyangiitis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 99. APAC Granulomatosis with Polyangiitis Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 100. APAC Granulomatosis with Polyangiitis Drug Revenue by Region (2018-2024) & (US$ Million)
Table 101. APAC Granulomatosis with Polyangiitis Drug Revenue by Region (2024-2034) & (US$ Million)
Table 102. APAC Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2018-2024) & (K Pcs)
Table 103. APAC Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 104. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 105. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 107. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 108. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 109. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 110. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 111. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 112. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 113. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 115. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 116. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2018-2024) & (K Pcs)
Table 118. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 119. Bionovis SA Company Information
Table 120. Bionovis SA Description and Overview
Table 121. Bionovis SA Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 122. Bionovis SA Granulomatosis with Polyangiitis Drug Product and Services
Table 123. Bionovis SA Granulomatosis with Polyangiitis Drug SWOT Analysis
Table 124. Bionovis SA Recent Developments
Table 125. Bristol-Myers Squibb Company Company Information
Table 126. Bristol-Myers Squibb Company Description and Overview
Table 127. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 128. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product and Services
Table 129. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug SWOT Analysis
Table 130. Bristol-Myers Squibb Company Recent Developments
Table 131. ChemoCentryx Inc Company Information
Table 132. ChemoCentryx Inc Description and Overview
Table 133. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 134. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product and Services
Table 135. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug SWOT Analysis
Table 136. ChemoCentryx Inc Recent Developments
Table 137. Coherus BioSciences Inc Company Information
Table 138. Coherus BioSciences Inc Description and Overview
Table 139. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 140. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product and Services
Table 141. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug SWOT Analysis
Table 142. Coherus BioSciences Inc Recent Developments
Table 143. Genor BioPharma Co Ltd Company Information
Table 144. Genor BioPharma Co Ltd Description and Overview
Table 145. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 146. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product and Services
Table 147. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug SWOT Analysis
Table 148. Genor BioPharma Co Ltd Recent Developments
Table 149. GlaxoSmithKline Plc Company Information
Table 150. GlaxoSmithKline Plc Description and Overview
Table 151. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 152. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product and Services
Table 153. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug SWOT Analysis
Table 154. GlaxoSmithKline Plc Recent Developments
Table 155. Iltoo Pharma Company Information
Table 156. Iltoo Pharma Description and Overview
Table 157. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 158. Iltoo Pharma Granulomatosis with Polyangiitis Drug Product and Services
Table 159. Iltoo Pharma Granulomatosis with Polyangiitis Drug SWOT Analysis
Table 160. Iltoo Pharma Recent Developments
Table 161. Panacea Biotec Ltd Company Information
Table 162. Panacea Biotec Ltd Description and Overview
Table 163. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 164. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product and Services
Table 165. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug SWOT Analysis
Table 166. Panacea Biotec Ltd Recent Developments
Table 167. Sandoz International GmbH Company Information
Table 168. Sandoz International GmbH Description and Overview
Table 169. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 170. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product and Services
Table 171. Sandoz International GmbH Granulomatosis with Polyangiitis Drug SWOT Analysis
Table 172. Sandoz International GmbH Recent Developments
Table 173. The International Biotechnology Center (IBC) Generium Company Information
Table 174. The International Biotechnology Center (IBC) Generium Description and Overview
Table 175. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 176. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product and Services
Table 177. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug SWOT Analysis
Table 178. The International Biotechnology Center (IBC) Generium Recent Developments
Table 179. Key Raw Materials Lists
Table 180. Raw Materials Key Suppliers Lists
Table 181. Granulomatosis with Polyangiitis Drug Distributors List
Table 182. Granulomatosis with Polyangiitis Drug Customers List
Table 183. Granulomatosis with Polyangiitis Drug Market Trends
Table 184. Granulomatosis with Polyangiitis Drug Market Drivers
Table 185. Granulomatosis with Polyangiitis Drug Market Challenges
Table 186. Granulomatosis with Polyangiitis Drug Market Restraints
Table 187. Research Programs/Design for This Report
Table 188. Key Data Information from Secondary Sources
Table 189. Key Data Information from Primary Sources
List of Figures
Figure 1. Granulomatosis with Polyangiitis Drug Product Picture
Figure 2. Global Granulomatosis with Polyangiitis Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Granulomatosis with Polyangiitis Drug Market Share by Type in 2022 & 2034
Figure 4. Benralizumab Product Picture
Figure 5. Avacopan Product Picture
Figure 6. Rituximab Biosimilar Product Picture
Figure 7. Others Product Picture
Figure 8. Global Granulomatosis with Polyangiitis Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 9. Global Granulomatosis with Polyangiitis Drug Market Share by Application in 2022 & 2034
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Granulomatosis with Polyangiitis Drug Report Years Considered
Figure 14. Global Granulomatosis with Polyangiitis Drug Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Granulomatosis with Polyangiitis Drug Revenue 2018-2034 (US$ Million)
Figure 16. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 17. Global Granulomatosis with Polyangiitis Drug Sales Quantity 2018-2034 (K Pcs)
Figure 18. Global Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Region (2018-2024)
Figure 19. Global Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Granulomatosis with Polyangiitis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 21. North America Granulomatosis with Polyangiitis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Granulomatosis with Polyangiitis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 23. Europe Granulomatosis with Polyangiitis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Granulomatosis with Polyangiitis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 25. China Granulomatosis with Polyangiitis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Granulomatosis with Polyangiitis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 27. APAC Granulomatosis with Polyangiitis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 29. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Granulomatosis with Polyangiitis Drug Sales Quantity in 2022
Figure 31. The Top 10 and Top 5 Players Market Share by Granulomatosis with Polyangiitis Drug Revenue in 2022
Figure 32. Granulomatosis with Polyangiitis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2018-2034)
Figure 35. Global Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2018-2034)
Figure 37. North America Granulomatosis with Polyangiitis Drug Revenue Market Share by Company in 2022
Figure 38. North America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Company in 2022
Figure 39. North America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2018-2034)
Figure 41. North America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2018-2034)
Figure 43. North America Granulomatosis with Polyangiitis Drug Revenue Share by Country (2018-2034)
Figure 44. North America Granulomatosis with Polyangiitis Drug Sales Quantity Share by Country (2018-2034)
Figure 45. U.S. Granulomatosis with Polyangiitis Drug Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Granulomatosis with Polyangiitis Drug Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Company in 2022
Figure 48. Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Company in 2022
Figure 49. Europe Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2018-2034)
Figure 51. Europe Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2018-2034)
Figure 53. Europe Granulomatosis with Polyangiitis Drug Revenue Share by Country (2018-2034)
Figure 54. Europe Granulomatosis with Polyangiitis Drug Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Granulomatosis with Polyangiitis Drug Revenue (2018-2034) & (US$ Million)
Figure 56. France Granulomatosis with Polyangiitis Drug Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Granulomatosis with Polyangiitis Drug Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Granulomatosis with Polyangiitis Drug Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Granulomatosis with Polyangiitis Drug Revenue (2018-2034) & (US$ Million)
Figure 60. China Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Company in 2022
Figure 61. China Granulomatosis with Polyangiitis Drug Revenue Market Share by Company in 2022
Figure 62. China Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2018-2034)
Figure 64. China Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2018-2034)
Figure 66. APAC Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Company in 2022
Figure 67. APAC Granulomatosis with Polyangiitis Drug Revenue Market Share by Company in 2022
Figure 68. APAC Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2018-2034)
Figure 70. APAC Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2018-2034)
Figure 72. APAC Granulomatosis with Polyangiitis Drug Revenue Share by Region (2018-2034)
Figure 73. APAC Granulomatosis with Polyangiitis Drug Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Granulomatosis with Polyangiitis Drug Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Granulomatosis with Polyangiitis Drug Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Granulomatosis with Polyangiitis Drug Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Granulomatosis with Polyangiitis Drug Revenue (2018-2034) & (US$ Million)
Figure 78. India Granulomatosis with Polyangiitis Drug Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Granulomatosis with Polyangiitis Drug Revenue Share by Country (2018-2034)
Figure 87. Brazil Granulomatosis with Polyangiitis Drug Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Granulomatosis with Polyangiitis Drug Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Granulomatosis with Polyangiitis Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Granulomatosis with Polyangiitis Drug Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Granulomatosis with Polyangiitis Drug Revenue (2018-2034) & (US$ Million)
Figure 92. Granulomatosis with Polyangiitis Drug Value Chain
Figure 93. Granulomatosis with Polyangiitis Drug Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed